CAS RN: 132539-06-1 | Product Number: O0393
* For order or inquiry, please contact
Our Authorized Distributors.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
|Purity / Analysis Method||>98.0%(GC)(T)|
|Molecular Formula / Molecular Weight||C__1__7H__2__0N__4S = 312.44|
|Physical State (20 deg.C)||Solid|
|Condition to Avoid||Heat Sensitive|
|Reaxys Registry Number||7655141|
|PubChem Substance ID||160871343|
|Merck Index (14)||6822|
|Appearance||Light yellow to Amber to Dark green powder to crystal|
|Purity(GC)||min. 98.0 %|
|Purity(Nonaqueous Titration)||min. 98.0 %|
|Melting point||192.0 to 196.0 °C|
|Melting Point||194 °C(dec.)|
|Solubility in water||Insoluble|
|Hazard Statements||H301 : Toxic if swallowed.
H315 : Causes skin irritation.
H319 : Causes serious eye irritation.
H413 : May cause long lasting harmful effects to aquatic life.
|Precautionary Statements||P501 : Dispose of contents/ container to an approved waste disposal plant.
P273 : Avoid release to the environment.
P270 : Do not eat, drink or smoke when using this product.
P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ eye protection/ face protection.
P302 + P352 : IF ON SKIN: Wash with plenty of water.
P337 + P313 : If eye irritation persists: Get medical advice/ attention.
P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P362 + P364 : Take off contaminated clothing and wash it before reuse.
P332 + P313 : If skin irritation occurs: Get medical advice/ attention.
P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth.
P405 : Store locked up.
|Customs Control Conditions (Q)|
Recently, it is reported that the use of olanzapine combined with a 5-HT3 receptor antagonist, a neurokinin1 (NK1) receptor antagonist and dexamethasone [D1961] has improved the control of acute chemotherapy-induced nausea and vomiting. (The product is for research purpose only.)
- Radioreceptor binding profile of the atypical antipsychotic olanzapine
- Binding of antipsychotic drugs to human brain receptors - focus on newer generation compounds
- 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release
- Olanzapine: An updated review of its use in the management of schizophrenia
- Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhea
- Pharmacokinetics and tissue distribution of olanzapine in rats
- Development of a stability-indicating HPLC method for simultaneous determination of olanzapine and fluoxetine in combined dosage forms
Safety Data Sheet (SDS) Search
The requested SDS is not available.
Please check that the Product Number you have entered is correct.
If your information is correct and you are still not able to view the requested SDS, please Contact Us for more information.